Atara Biotherapeutics Balance Sheet

Financials in millions USD. Fiscal year is January - December.

Millions USD. Fiscal year is Jan - Dec.

Year	2023	2022	2021	2020	2019	2018	2017	2016	2015	2014	2013
Cash & Equivalents	25.99	93.09	106.28	200.6	74.51	60.89	79.42	48.16	23.94	21.9	Upgrade
Short-Term Investments	25.88	149.88	264.98	300.26	184.79	248.93	86.87	207.71	296.74	82.22	Upgrade
Cash & Cash Equivalents	51.87	242.97	371.26	500.85	259.3	309.83	166.29	255.88	320.68	104.12	Upgrade
Cash Growth	-78.65%	-34.56%	-25.87%	93.15%	-16.31%	86.32%	-35.01%	-20.21%	208.00%	101.72%	Upgrade
Receivables	34.11	40.22	0.99	1.25	0	0	0	0	0	0	Upgrade
Inventory	9.71	1.59	0	0	0	0	0	0	0	0	Upgrade
Other Current Assets	6.18	10.31	12.37	21.17	13.69	11.66	5.9	4.68	3.92	1.91	Upgrade
Total Current Assets	101.87	295.08	384.62	523.27	272.99	321.49	172.19	260.55	324.6	106.03	Upgrade
Property, Plant & Equipment	58.79	74.32	79.94	62.82	68.18	68.58	44.13	3.26	0.27	0.05	Upgrade
Long-Term Investments	0	0	1.2	1.2	1.2	1.2	1.2	0	0	0	Upgrade
Other Long-Term Assets	4.84	7.02	2.37	0.83	0.57	0.57	0.26	0.1	0.11	0.05	Upgrade
Total Long-Term Assets	63.64	81.34	83.51	64.85	69.95	70.35	45.59	3.36	0.38	0.1	Upgrade
Total Assets	165.5	376.42	468.13	588.12	342.94	391.84	217.78	263.91	324.98	106.12	Upgrade
Accounts Payable	3.68	6.87	17.37	7.12	7.96	3.72	14.71	2.78	1.45	0.44	Upgrade
Deferred Revenue	115.4	85	96.47	61.25	0	0	0	0	0	0	Upgrade
Other Current Liabilities	23.15	-12.96	-8.05	14.53	28.78	36.26	12.94	6.9	8.26	2.28	Upgrade
Total Current Liabilities	142.23	78.92	105.79	82.9	36.74	39.98	27.65	9.68	9.71	2.72	Upgrade
Long-Term Debt	80.32	88.3	25.52	13.04	14.14	0	0	0	0	0	Upgrade
Other Long-Term Liabilities	42.19	82.56	57.21	29.84	1.28	13	12.27	0.5	0.17	0.22	Upgrade
Total Long-Term Liabilities	122.51	170.86	82.73	42.88	15.42	13	12.27	0.5	0.17	0.22	Upgrade
Total Liabilities	264.74	249.78	188.51	125.78	52.16	52.98	39.92	10.18	9.88	2.94	Upgrade
Total Debt	80.32	88.3	25.52	13.04	14.14	0	0	0	0	0	Upgrade
Debt Growth	-9.04%	246.03%	95.68%	-7.75%	-	-	-	-	-	-	Upgrade
Retained Earnings	-1,969.15	-1,693.02	-1,464.72	-1,124.58	-817.96	-527.35	-296.65	-177.16	-98.11	-40.89	Upgrade
Comprehensive Income	-0.2	-2.07	-0.37	0.3	0.22	-0.34	-0.15	-0.18	-0.52	-0.1	Upgrade
Shareholders' Equity	-99.23	126.64	279.61	462.34	290.78	338.86	177.86	253.74	315.1	103.18	Upgrade
Net Cash / Debt	-28.45	154.67	345.74	487.81	245.17	309.83	166.29	255.88	320.68	104.12	Upgrade
Net Cash / Debt Growth	-	-55.27%	-29.12%	98.97%	-20.87%	86.32%	-35.01%	-20.21%	208.00%	101.72%	Upgrade
Net Cash Per Share	-0.27	1.52	3.69	6.59	4.78	7.07	5.57	8.91	12.53	20.88	Upgrade
Working Capital	-40.36	216.16	278.84	440.37	236.25	281.51	144.54	250.88	314.89	103.3	Upgrade
Book Value Per Share	-0.94	1.24	2.98	6.25	5.67	7.74	5.96	8.83	12.32	20.69	Upgrade

Source: Financials are provided by Nasdaq Data Link and sourced from the audited annual (10-K) and quarterly (10-Q) reports submitted to the Securities and Exchange Commission (SEC).